This unique 1,200-page report contains 450 tables, and provides test volume and sales forecasts for major tumor markers, as well as supplier sales and shares by test, market segment and country. Available by country and section.
This comprehensive seven-country report identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next ten years; examines trends in the U.S., five major European countries (France, Germany, Italy, Japan, UK) and Japan; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.